A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials

Andrew P. D. Henderson,1 Daniel R. Altmann,2 Anand S. Trip,1 Constantinos Kallis,2 Steve J. Jones,3 Patricio G. Schlottmann,4 David F. Garway-Heath,4 Gordon T. Plant5 and David H. Miller1

1 NMR Research Unit, Institute of Neurology, University College London, London, WC1N 3BG, UK
2 Medical Statistics Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
3 Department of Clinical Neurophysiology, National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK
4 Glaucoma Research Unit, Moorfields Eye Hospital, City Road, London, EC1V 2PD, UK
5 Department of Neurology, The National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK

Correspondence to: Andrew P. D. Henderson,
NMR Research Unit, Institute of Neurology,
University College London, London,
WC1N 3BG, UK
E-mail: a.henderson@ion.ucl.ac.uk

Following an episode of optic neuritis, thinning of the retinal nerve fibre layer, which indicates axonal loss, is observed using optical coherence tomography. The longitudinal course of the retinal changes has not been well characterized. We performed a serial optical coherence tomography study in patients presenting with optic neuritis in order to define the temporal evolution of retinal nerve fibre layer changes and to estimate sample sizes for proof-of-concept trials of neuroprotection using retinal nerve fibre layer loss as the outcome measure. Twenty-three patients (7 male, 16 female, mean age 31 years) with acute clinically isolated unilateral optic neuritis were recruited to undergo optical coherence tomography, visual assessments and visual evoked potentials at presentation (median 16 days from onset of visual loss) and after 3, 6, 12 and 18 months. Compared with the clinically unaffected fellow eye, the retinal nerve fibre layer thickness of the affected eye was significantly increased at presentation and significantly reduced at all later time points. The evolution of retinal nerve fibre layer changes in the affected eye fitted well with an exponential model, with thinning appearing a mean of 1.6 months from symptom onset and the rate of ongoing retinal nerve fibre layer loss decreasing thereafter. At presentation, increased retinal nerve fibre layer thickness was associated with impaired visual acuity and prolonged visual evoked potential latency. Visual function after 12 months was not related to the extent of acute retinal nerve fibre layer swelling but was significantly associated with the extent of concurrent retinal nerve fibre layer loss. Sample size calculations for placebo-controlled trials of acute neuroprotection indicated that the numbers needed after 6 months of follow up are smaller than those after 3 months and similar to those after 12 months of follow-up. Study power was greater when investigating differences between clinically unaffected and affected eyes rather than retinal nerve fibre layer thickness of the affected eye alone. Inflammation in the optic nerve and impaired axonal transport (implied by retinal nerve fibre layer swelling) are associated with visual dysfunction and demyelination (long visual evoked potential latency) during acute optic neuritis. Retinal nerve fibre layer thinning is usually evident within 3 months. Optical coherence tomography-measured retinal nerve fibre layer loss after 6 months is a suitable outcome measure for proof-of-concept trials of acute neuroprotection in optic neuritis.
Introduction

The initial presentation and early clinical course of multiple sclerosis, in most patients, is characterized by acute episodes of neurological dysfunction that are known as relapses. Such episodes are due to development of new inflammatory demyelinating lesions in central nervous system white matter. While most relapses will be followed by a partial or complete recovery of neurological function, a minority will result in permanent functional deficits. It is thought that axonal damage and loss occurring in the acute inflammatory lesion are the main pathological substrates of incomplete recovery (Ferguson et al., 1997; Trapp et al., 1998).

One of the most common and characteristic syndromes at the onset or during the course of the relapsing remitting phase of multiple sclerosis is an episode of acute optic neuritis, which results from the development of an inflammatory demyelinating lesion in the optic nerve. The anterior visual pathway, including the optic nerve and retinal nerve fibre layer (RNFL), has been suggested as a particularly suitable site for studying the pathophysiology and treatment of acute inflammatory demyelinating central nervous system lesions that occur in optic neuritis and multiple sclerosis (Kolappan et al., 2009). The functions of the optic nerve are quantifiable both clinically (with quantitative tests of visual function including acuity, fields and colour vision) and electrophysiologically (by measuring the visual evoked potential). The optic nerve can also be imaged using MRI to elucidate the extent and nature of structural abnormalities in the symptomatic lesion. Importantly, the development of axonal loss can also be inferred by imaging the RNFL using optical coherence tomography.

In a serial study of the optic nerve following a single episode of optic neuritis, Hickman and colleagues (2004) found initial swelling of the diseased optic nerve, which declined over time with the nerve being atrophic compared with the fellow eye after 1 year. Using the measurements of the optic nerve atrophy to infer axonal loss is unfortunately confounded by accompanying myelin loss. However, the axons of the retinal ganglion cells, which form the optic nerve, are unmyelinated in the RNFL. In the RNFL, the axons form the bulk of the tissue (Ogden, 1984) and so reductions in its thickness are likely to relate more directly to loss of ganglion cell axons (the same fibres that travel in the optic nerve). Whilst it is known that retinal vessels attenuate with retinal atrophy, blood vessels form only a small proportion of retinal tissue (Hood et al., 2008). The RNFL can be quantified in life with optical coherence tomography (Huang et al., 1991).

Axonal loss in the retina, as a consequence of optic neuritis, can sometimes be directly seen in the retina (Frisén and Hoyt, 1974; Sharpe and Sanders, 1975), and has been documented and quantified using optical coherence tomography in cross-sectional studies of patients with multiple sclerosis (Parisé et al., 1999) and clinically isolated optic neuritis (Trip et al., 2005; Costello et al., 2006; Klistorner et al., 2008). Costello and colleagues (2008) studied a group of patients at varying intervals following a single episode of optic neuritis, and observed no further RNFL loss 6 months after symptoms began.

There have been no systematic longitudinal studies of acute optic neuritis using optical coherence tomography to follow changes over time in the RNFL, and no studies have serially looked at changes in the macula. Whilst the study by Costello and colleagues (2008) was predominantly cross-sectional at various time points, it included a subset of 20 patients followed from one to 3 months after onset of symptoms up to 12 months. It was unclear, however, what the exact nature of the time course was, and whether swelling of the RNFL (as seen in two other small cohorts) (Menke et al., 2005; Pro et al., 2006) was a characteristic early finding, Hickman and colleagues (2004a) observed ongoing loss of optic nerve mean area more than a year after unilateral optic neuritis and it is unclear whether this is also seen in the RNFL and macula.

We designed a prospective, systematic longitudinal optical coherence tomography study in a cohort of patients presenting with optic neuritis, the aims of which were to:

(a) characterize, with appropriate statistical models, the time-course of (i) early RNFL swelling that reflects inflammation in the optic nerve and/or interruption of axonal transport (Kallenbach et al., 2010); and (ii) subsequent RNFL thinning that implies axonal loss following optic neuritis;
(b) investigate whether RNFL swelling during acute optic neuritis predicts later axonal loss and visual outcome;
(c) report serial macular volume changes following acute optic neuritis; and
(d) estimate sample sizes for clinical trials of neuroprotective agents in acute optic neuritis that use optical coherence tomography-measured RNFL loss as the outcome measure.

Materials and methods

Patients

Twenty-three patients with their first episode of acute unilateral optic neuritis (7 male, 16 female, median age 31 years, range 21–49 years) were recruited from the neuro-ophthalmology clinic, Moorfields Eye Hospital, London. There was no prior history of clinical events suggesting demyelination elsewhere in the central nervous system, i.e. patients had clinically isolated unilateral optic neuritis at study entry. The delay from onset of symptoms to first study examination was 16 days, range 10–32 days. All patients were examined acutely, and then at 3, 6, 12 and 18 months after onset of symptoms. At each visit, a neurological assessment was undertaken and brain MRI was obtained and analysed for the presence of lesions compatible with

Keywords: optic neuritis; optical coherence tomography; sample size estimates; retinal nerve fibre layer; axonal loss

Abbreviations: logMAR = logarithm of the minimum angle of resolution; RNFL = retinal nerve fibre layer; TES = total error score
demyelination and for fulfilment of the McDonald criteria for multiple sclerosis (Polman et al., 2005). Some patients had missing time points. No patient had recurrent or contralateral optic neuritis during or prior to the study period.

Approval was obtained for the study from the National Hospital for Neurology and Neurosurgery and University College London Institute of Neurology Joint Research Ethics Committee; informed consent was obtained from each patient, in accordance with the Declaration of Helsinki.

**Optical coherence tomography**

Optical coherence tomography images were acquired with a time domain optical coherence tomography (Stratus OCT Model 3000; Carl Zeiss Meditec, Dublin, CA, USA). RNFL images were acquired by taking three circular 3.4 mm scans, centred on the optic disc, the mean of which was used to express RNFL thickness (Fast RNFL thickness protocol). The thicknesses of the quadrants of the RNFL were automatically calculated by the optical coherence tomography device software. Variability of the size of the optic disc accounts for a small proportion of the variability of the RNFL thickness (Baaleau et al., 2009) and adjusting the scan circle diameter does not account for this variation (Kauhik et al., 2009); accordingly, we did not adjust the RNFL measures for disc diameter. Macular thickness maps were acquired by making six radial scans centred on the fovea, and by construction of a map from these scans (Fast macular thickness map scanning protocol). Optical coherence tomography images are given a signal strength by the Stratus optical coherence tomography device, with a maximum of 10. Optical coherence tomography images were rejected if an individual eye was <7, the inter-eye signal strength difference was >2, or if the difference in signal strength between baseline and follow-up scans was >2.

Twelve control subjects (five male, seven female, median age 31 years, range 24–50 years) were also imaged, on two occasions, a median of 552 days (range 350–907 days) apart, with the scanning dates spanning a similar duration of time as the study of optic neuritis patients.

**Visual assessments**

Patients were examined at each visit. Visual acuity was measured (un-aided, with appropriate refraction or with pinhole correction) using a retro-illuminated early treatment diabetic retinopathy study chart and recorded as the 4 m logarithm of the minimum angle of resolution (logMAR) acuity (Ferris et al., 1982). In addition, Sloan 1.25% contrast early treatment diabetic retinopathy study charts were used at 4 m to calculate the equivalent low-contrast visual acuity. When no letters could be identified correctly, a score of 1.7 was assigned (Optic Neuritis Study Group, 1991). Colour vision was measured with Farnsworth-Munsell 100 Hue colour test (Farnsworth, 1943) and analysis was performed on the square root of the total error score (VTES), as this is normally distributed. Central visual field sensitivity was analysed using the 30-2 program on the Humphrey field analyser (Carl Zeiss Meditec, Dublin, CA, USA). Wide angle lenses were used to correct refractive errors when necessary. The overall field mean deviation was derived from control data provided by the manufacturer. A mean deviation of -35 dB was assigned when vision was too poor to attempt the test (Kupersmith et al., 2002). For the purposes of comparing the models of RNFL thickness and macular volume changes, two subgroups were defined according to the degree of visual recovery at or after 12 months. ‘Good’ visual recovery was defined as a logMAR acuity ≤0.1 and ‘poor’ recovery as logMar >0.1. The good level of recovery is exhibited by a majority of optic neuritis patients (Beck et al., 1994), and is a level at which at least one of colour vision, visual field sensitivity and contrast sensitivity are likely to be normal (Trobe et al., 1996).

**Visual evoked potentials**

Patient central field pattern reversal visual evoked potentials were measured on each study visit using methods previously described (Brusa et al., 2001).

**Statistical methods**

Paired t-tests were used to assess differences between affected and fellow eyes in patients at fixed time points. Comparisons of patients’ affected and fellow eyes with control eye values were made by unpaired t-tests between each patient eye and a single randomly selected eye per control.

Changes in controls’ retinal optical coherence tomography measures over time were assessed using mixed effects linear regression. For comparison with patients’ clinically unaffected eyes, patient indicator time interaction terms were used.

Linear regression was used to investigate relationships between retinal measures and quantitative measures of vision and visual evoked potentials. Where residuals could not be assumed to be normal, non-parametric bias-corrected bootstrap (Efron and Tibshirani, 1993) estimates (1000 replicates) were obtained. The bootstrap samples are resamplings from the data to produce confidence limits from the observed variability, rather than use parametrically derived standard errors; it is standardly used when either parametric assumptions do not hold, or when estimating functions of several parameters where there is no theoretically derivable standard error.

The time course for changes in retinal values was assessed using an exponential model (Snedecor and Cochrane, 1989) similar to that used previously for visual recovery (Hickman et al., 2004b) and serial optic nerve MRI changes (Hickman et al., 2004a); such exponential models are optimal for modelling an early rapid change which slows to settle at an eventual final value. Such a time course is plausible a priori for visual function, but less so for RNFL and macular volume; however, the raw data supported this type of course (Figs 1 and 3). As a precaution, two alternative models were examined (polynomial time models were not considered as they tend artefactually to impose curves at the extremes): (i) regressing retinal values on log time,
Retinal changes after optic neuritis

Brain 2010: 133; 2592–2602 | 2595

which has a similar decelerating rate as an exponential model but with continued decline (i.e. without settling at a final value); and (ii) a saturated means model which, by simultaneously fitting the mean retinal value at each time point, is the best possible fit. Although this latter model has the disadvantage of not being useful for interpretation, since it treats retinal values as unrelated over time, it is a convenient benchmark against which to assess the fit of other models. R² values were used to compare model fit. Exponential modelling of both the RNFL and macular volume was carried out both for the affected eye retinal value and for the difference between the affected eye and the baseline fellow eye value.

The algebraic form of the exponential model used (shown here without the detailed error structure that is described in the online supplementary material) is:

\[ y = a + \beta \exp(-\gamma t), \]  

where \( y \), the response variable, is the nerve fibre layer thickness, \( t \) is months from onset, \( a \) represents the asymptote, or predicted eventual RNFL thickness, \( \beta \) is the absolute value of the drop between the initial value and the asymptote, and \( \gamma \) controls the tightness of the curve. The model yields: (i) an estimate of the final value (not necessarily the level at the last assessment), given by \( a \); (ii) the rates of change at a given time, given by \(-\beta \exp(-\gamma t)\); (iii) times to achieve a given fraction \( d \) of the total change from start to final value, given by \(-1/\gamma \ln(1-d)\); and (iv) times to achieve zero value, given by \((1/\gamma) \ln(-\beta/a)\); this was calculated when \( y \) was affected minus baseline fellow eye value, where zero estimates a point where atrophy begins relative to the fellow eye value. Results are reported from a hierarchical model of this form, implemented in Windows Bayesian interference Using Gibbs Sampling (WinBUGS) software (Lunn et al., 2000) with details given in the Supplementary material. The modelling assumes that any missing data points are missing at random.

Sample size estimates for two-arm trials measuring RNFL of 3, 6 and 12 month duration were based on means and standard deviations obtained directly from the data at the three time points for affected eye RNFL and affected minus baseline fellow RNFL; and on Pearson correlation coefficients between baseline fellow and affected RNFL values at the three time points. Estimates were calculated for two-tailed tests at \( \alpha=0.05 \), for 80 and 90% power, to detect treatment effects of 0.20 to 0.80%, where 100% treatment effect was taken as the mean difference: follow-up (3, 6 or 12 month) affected eye RNFL minus baseline fellow eye RNFL. Confidence intervals (CIs) for selected sample sizes were obtained using the bootstrap method described above. Calculations, using standard methods (Senn, 1997) were for three between-arm comparisons, in order of increasing theoretical efficiency.

(i) Method A: mean follow-up affected RNFL, using follow-up affected RNFL standard deviation (and ignoring fellow eye value, as would be advisable when there is a history of prior optic neuritis in the fellow eye).

(ii) Method B: mean difference follow-up affected RNFL minus baseline fellow eye RNFL, using the standard deviation of this difference.

(iii) Method C: mean follow-up affected RNFL adjusted for baseline fellow eye RNFL, using the follow-up affected RNFL standard deviation and the follow-up affected versus baseline fellow Pearson correlation coefficient (Senn, 1997). Sample sizes for Method C are functions of the treatment effect, the affected RNFL standard deviation and the baseline fellow versus follow-up affected eye RNFL correlation coefficient.

All statistical analyses except the hierarchical exponential model were performed in Stata 9.2 (Stata Corp, College Station, TX).

Results

Patient clinical details

During the study, four patients experienced a second clinical episode of demyelination (all in their spinal cord) and were diagnosed with multiple sclerosis. A further eight patients did not experience a second clinical episode of demyelination but fulfilled the McDonald criteria for the diagnosis of multiple sclerosis (Polman et al., 2005) on the basis of changes on brain MRI. Of the remainder of the patients, nine had MRI changes consistent with inflammatory demyelination, but not fulfilling the McDonald criteria. Two patients had no brain lesions. No patient received intravenous glucocorticosteroids during the acute optic neuritis episode and none were treated with multiple sclerosis disease modifying therapy during the course of the study.

Patient clinical measures in affected nerves

At baseline, in affected eyes, the mean [standard deviation (SD)] logMAR acuity was 0.52 (0.73) (median 0.04, range 0.10 to 1.70), the mean (SD) Sloan 1.25% contrast acuity was 1.30 (0.46) (median 1.66, range 0.52 to 1.70), the mean (SD) whole field mean deviation was -13.0 (12.8) (median -7.0, range -33.0 to 0.0) and the mean (SD) TES was 19.3 (11.1) (median 13.3, range 7.8-36.6). Twenty-one of the 23 patients had eye pain at presentation, 20 had a relative afferent papillary defect, and eight had swelling of the optic disc visible with a hand held ophthalmoscope.

At 12 months, in affected eyes, the mean (SD) logMAR acuity was 0.08 (0.25) (median 0.02, range -0.12 to 0.94), the mean (SD) Sloan 1.25% contrast acuity was 0.97 (0.48) (median 0.78, range 0.44 to 1.7), the mean (SD) whole field mean deviation was -5.0 (6.1) (median -4.3, range -27.0 to 0.25) and the mean (SD) TES was 12.3 (5.0) (median 11.3, range 6.6 to 22.7). Thirteen of the patients had developed pallor of the optic disc in the affected eye and six had a residual relative afferent pupillary defect. Five of the patients were classified as having a poor visual recovery (logMAR acuity > 0.1).

Control retinal measures

At baseline, the median RNFL thickness for controls was 106.7 μm (mean 105.4, SD 9.7, range 90.1 to 118.1). At 18 months, the mean RNFL thickness was 104.1 μm (SD 11.3). This decrease was not significant [mean loss 0.004 μm per day, 95% CI 0.009, 0.000; P=0.076].

At baseline, the mean macular volume was 6.83 mm³ (SD 0.28). At 18 months, the mean macular volume was 6.88 mm³ (SD 0.28), and the increase was not significant (mean increase 0.0001 mm³ per day, 95% CI 0.0000, 0.0002; P=0.104).
Patients' healthy contralateral (fellow eye) retinal measures

At baseline, the median RNFL thickness for the patients' healthy unaffected eyes was 101.0 μm (mean 103.0 μm, SD 9.6, range 88.3–124.2), not significantly different from healthy control values \( (P = 0.711) \) (Table 1). There was a small, but significant decrease over time in fellow eye RNFL (mean loss 0.005 μm per day, 95% CI 0.002, 0.008; \( P = 0.002 \)), but this gradient was not significantly different from that seen in controls (patient-control gradient difference \(-0.0004\) μm per day, 95% CI \(-0.0055, 0.0046\); \( P = 0.861 \)).

The mean macular volume of patients' fellow eyes was 6.89 mm³ (SD 0.39), not significantly different from healthy control values \( (P = 0.670) \). There was no significant change over time in patient fellow eye macular volume values (gradient of change \(-0.0001\) mm³ per day, 95% CI \(-0.0002, 0.0000\); \( P = 0.055 \)), and there was no difference in patient fellow eye and healthy control gradients (patient-control gradient difference \(-0.0001\), 95% CI \(-0.0003, 0.0000\); \( P = 0.217 \)).

Patients' affected optic nerve retinal measures

RNFL thickness

At baseline, the median thickness of patients' diseased RNFL was 116.5 μm (mean 132.8 SD 48.8, range 86.9–280.9), which was significantly increased compared to fellow eyes \( (P = 0.006) \), and on the borderline of significance when compared with control eyes \( (P = 0.050) \). The estimated values of the exponential model parameters were: \( \alpha = 86.52 \) (95% CI: 79.11, 94.4; \( P < 0.05 \)), \( \beta = 82.22 \) (CI: 43.23, 122.4; \( P < 0.05 \)), \( \gamma = 0.9764 \) (CI: 0.8307, 1.182; \( P < 0.05 \)) (Fig. 1).

The estimated rates of change in RNFL thickness in patients' affected eyes are shown in Table 2. Using this model the mean time to 50% loss from initial values to the asymptote value was 0.72 months (95% CI 0.59, 0.83; \( P < 0.05 \)), the mean time to 90% loss was 2.38 months (95% CI 1.95, 2.77; \( P < 0.05 \)) and 99% of the loss from the initial value to the asymptotic value had occurred by a mean of 4.75 months (95% CI 3.90, 5.54; \( P < 0.05 \)). At final follow-up, affected eye RNFL thickness was significantly smaller than controls \( (P < 0.001) \).

The time of first detectable atrophy compared with the baseline fellow eye value was 1.64 months (95% CI 0.96, 2.32; \( P < 0.05 \)). The parameter estimates for this portion of the model (affected minus baseline RNFL thickness) were: \( \alpha = -16.55 \), \( \beta = 83.14 \) and \( \gamma = 0.983 \) (Fig. 2).

When the patients were divided by visual recovery status, there was no significant difference between baseline RNFL thickness \( (P = 0.980) \), but those with a poor recovery \( (n = 5) \) had a larger drop from baseline to 3 month RNFL \( (P = 0.002) \). Those patients with poor recovery had a significantly lower asymptote than those with a good recovery \( (\alpha_{\text{NR}} = 66.78 \% \text{ CI} 54.32, 79.43; \alpha_{\text{GR}} = 92.5 \% \text{ CI} 85.69, 99.36) \), difference in \( \alpha = 25.72, 95\% \text{ CI} 11.06, 39.36; P < 0.05 \). The \( \beta \) and \( \gamma \) parameters could not be reliably estimated in the subgroups.

### Table 1 Patient RNFL measures at study time points

<table>
<thead>
<tr>
<th>Baseline</th>
<th>3 months</th>
<th>6 months</th>
<th>12 months</th>
<th>18 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median days elapsed since symptom onset (range)</td>
<td>16 (10, 32)</td>
<td>92 (76, 136)</td>
<td>195 (167, 264)</td>
<td>393 (333, 450)</td>
</tr>
<tr>
<td>Affected eye RNFL thickness, μm</td>
<td>116.4 (86.9, 280.9)</td>
<td>94.6 (52.2, 113.7)</td>
<td>88.5 (45.2, 108.2)</td>
<td>85.3 (18.3, 163.3)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>132.0 (49.8)</td>
<td>92.8 (16.2)</td>
<td>85.3 (18.3)</td>
<td>83.3 (16.3)</td>
</tr>
<tr>
<td>Fellow eye RNFL thickness, μm</td>
<td>101.1 (88.3, 124.2)</td>
<td>96.5 (52.2, 113.7)</td>
<td>98.3 (45.2, 108.2)</td>
<td>93.3 (18.3, 163.3)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>103.0 (9.6)</td>
<td>92.8 (16.2)</td>
<td>85.3 (18.3)</td>
<td>83.3 (16.3)</td>
</tr>
<tr>
<td>Affected eye macular volume, mm³</td>
<td>6.90 (6.16, 8.11)</td>
<td>6.52 (5.63, 7.26)</td>
<td>6.59 (5.03, 7.31)</td>
<td>6.34 (5.46, 7.31)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>6.96 (0.43)</td>
<td>6.58 (0.38)</td>
<td>6.38 (0.40)</td>
<td>6.34 (0.40)</td>
</tr>
<tr>
<td>Fellow eye macular volume, mm³</td>
<td>6.78 (6.30, 7.87)</td>
<td>6.89 (6.30, 7.87)</td>
<td>6.89 (6.30, 7.87)</td>
<td>6.89 (6.30, 7.87)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>6.88 (0.36)</td>
<td>6.88 (0.36)</td>
<td>6.88 (0.36)</td>
<td>6.88 (0.36)</td>
</tr>
</tbody>
</table>

Downloaded from https://academic.oup.com/brain/article-abstract/133/9/2592/351387 by guest on 28 July 2018
Macular volume
At baseline, patients' affected eye macular volume (median macular volume 6.90 mm$^3$, range 6.16–8.11; mean macular volume 6.91 mm$^3$, SD 0.36) was similar to the fellow eye macular volume (median fellow eye macular volume 6.78, range 6.54–7.36; mean macular volume 6.89, SD 0.39), and to the control eye value ($P=0.371$). The change in macular volume over time was modelled by an exponential function with the parameters as defined for RNFL. The absolute values of the parameters were: $\alpha/21.65$ (95% CI: 20.14, 23.8; $P<0.001$), $\beta0.789$ (95% CI: 0.522, 1.085; $P<0.001$), $\gamma0.418$ (95% CI: 0.294, 0.686; $P<0.001$) (Figs 3, 4).

The estimated rates of change in patients' affected eye macular volume are shown in Table 3. The predicted time to 50% loss of macular volume was 1.66 months (95% CI 0.99, 2.29; $P<0.05$), and to 90 and 99% loss of macular volume 5.52 months (95% CI 3.28, 7.61; $P<0.05$) and 11.03 months (95% CI 6.56, 15.22; $P<0.05$), respectively. At final follow-up, affected eye macular volume was significantly smaller than controls ($P<0.001$).

Model fit
The exponential model was found to fit the data well: for both RNFL and macular volume, $R^2$ goodness-of-fit values for the exponential model (RNFL 0.351, macular volume 0.272) were only slightly lower than for the saturated means model (RNFL 0.352, macular volume 0.273) but substantially higher than for the log time model (RNFL 0.320, macular volume 0.260), thus justifying the choice of exponential model.

Relationship of early loss to final retinal outcome
Greater loss of RNFL thickness between baseline and 3 months predicted lower final RNFL thickness (for every 1 mm of loss between baseline and 3 months there was 1.05 mm of loss at 12 months, 95% CI 0.78, 1.32; $P<0.001$). This effect was similar in those with good and poor recovery.

Relationship of early swelling to later RNFL loss
The degree of swelling (i.e. affected minus fellow eye values) observed in the RNFL at baseline did not determine degree of RNFL reduction compared with the fellow eye at 12 months (observed coefficient 0.13 mm of RNFL loss observed at 12 months for every 1 mm of RNFL swelling at baseline, 95% CI 0.02, 0.28; $P=0.093$), nor did the degree of swelling in the macula influence the eventual macular volume (observed coefficient 0.14 mm$^3$ of macular volume loss at 12 months for every 1 mm$^3$ of macular volume swelling at baseline, 95% CI 0.02, 0.8; $P=0.754$).

Relationships with vision
Higher baseline RNFL thickness of the affected eye was associated with (i) worse baseline logMAR visual acuity (logMAR acuity 0.007 units higher for 1 mm increase in RNFL thickness, 95% CI 0.001, 0.014; $P=0.020$); (ii) lower baseline visual mean field deviation (visual field mean deviation 0.129 dB lower for each 1 mm...
Table 3  Estimated rates of reduction in macular volume

<table>
<thead>
<tr>
<th>Time (from first measurement)</th>
<th>Rate of atrophy (mm³ per month)</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>At first measurement</td>
<td>−0.33</td>
<td>−0.50−0.02</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>15 days</td>
<td>−0.27</td>
<td>−0.45−0.16</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>1 month</td>
<td>−0.22</td>
<td>−0.33−0.14</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>3 months</td>
<td>−0.09</td>
<td>−0.13−0.06</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>4 months</td>
<td>−0.06</td>
<td>−0.09−0.04</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>5 months</td>
<td>−0.04</td>
<td>−0.07−0.02</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>6 months</td>
<td>−0.03</td>
<td>−0.05−0.01</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>12 months</td>
<td>−0.002</td>
<td>−0.007−0.000</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Figure 4  Affected minus baseline fellow macular volume with fitted exponential model. The interrupted line represents the level at which the affected and fellow eye have the same value.

increase in RNFL thickness, 95% CI −0.227, −0.031; P = 0.009; Fig. 5); and (iii) worse colour vision (for each 1 µm increase in RNFL thickness, ∧TES increased by 0.118, 95% CI 0.029, 0.205; P = 0.012). Baseline macular volume was not correlated with logMAR visual acuity (P = 0.526) or colour vision (P = 0.781). The relationship of macular volume and whole visual field was not tested as it was felt that this was biologically inappropriate. No single quadrant of the RNFL was a better predictor of visual acuity or colour vision at baseline than the circumpapillary (whole) RNFL measure.

At 12 months, lower RNFL thickness was associated with: (i) worse logMAR acuity (observed coefficient −0.008, 95% CI −0.017, 0.000; P = 0.018); (ii) lower visual field mean deviation (observed coefficient 0.194, 95% CI −0.016, 0.403; P = 0.023); and (iii) worse colour vision (for each 1 µm decrease in RNFL thickness, ∧TES decreased by 0.236, 95% CI 0.134, 0.334; P < 0.001). At the same time, lower macular volume was associated with worse colour vision (for each 1 mm³ reduction in macular volume, ∧TES decreased by 8.71, 95% CI 4.11, 13.3; P = 0.004), but not logMAR acuity (P = 0.114). The degree of RNFL swelling at baseline did not predict either logMAR acuity (observed coefficient 0.00 95% CI 0.00, 0.00; P = 0.899) or visual field mean deviation (observed coefficient −0.13, 95% CI −0.08, 0.05; P = 0.667) at 12 months.

Higher (i.e. worse) baseline logMAR acuity was associated with lower RNFL thickness at 12 months (RNFL thickness 1.42 µm lower for every 0.1 increase in logMAR acuity, 95% CI 0.58, 2.26; P = 0.002; R² = 0.43), and higher baseline Sloan 1.25% contrast acuity was associated with lower RNFL thickness at 12 months (RNFL thickness 2.24 µm lower for every 0.1 increase in Sloan 1.25% contrast acuity, 95% CI 0.21, 4.28; P = 0.033, R² = 0.30).

Association with visual evoked potentials

At baseline, higher diseased RNFL thickness predicted longer visual evoked potential latency (visual evoked potential latency 0.266 ms longer for each 1 µm increase in RNFL thickness, 95% CI 0.072, 0.460; P = 0.040). The relationship between diseased RNFL thickness and visual evoked potential amplitude did not reach significance (observed coefficient 0.043 mV decrease in visual evoked potential amplitude for every 1 µm increase in RNFL thickness, 95% CI −0.082, −0.003; P = 0.076). At 6 months, lower diseased RNFL thickness was associated with lower visual evoked potential amplitude (observed coefficient 0.109 mV decrease in visual evoked potential amplitude for every 1 µm decrease in RNFL thickness, 95% CI 0.003, 0.217; P = 0.045), but there was no significant relationship between visual evoked potential latency and RNFL thickness (observed coefficient visual evoked potential latency 0.077 ms longer for every 1 µm decrease in RNFL thickness, 95% CI −0.053, 0.378; P = 0.721). At 12 months, lower diseased RNFL thickness was associated with lower visual evoked potential amplitude (observed coefficient 0.166 mV decrease in visual evoked potential amplitude for every 1 µm decrease in RNFL thickness, 95% CI 0.053, 0.279; P = 0.009), but there was no relationship between visual evoked potential latency and diseased RNFL thickness (observed coefficient −0.123, 95% CI −0.623, 0.376; P = 0.609).

Sample size estimates

Sample size calculations used the following estimates from the data, for 3, 6 and 12 months, respectively: affected eye RNFL SD 16.16, 18.32 and 16.34 µm; mean (SD) of the affected–fellow eye at 12 months are given in Table 4. The design which adjusted for the fellow eye value and used analysis of covariance (Method C) analysis was the most powerful, followed by the comparison of affected eye–fellow eye differences. The study design with no adjustment for fellow eye values (Method A) was the least powerful. For Method C, with 12-month duration, 80% power and 30 and 50% treatment effects, sample sizes were 100 (95% CI 56, 246) and 36 (95% CI 20, 89), respectively; and for 6-month duration, corresponding sample sizes were 97 (95% CI 54,197) and 35 (95% CI 20, 71).
Discussion

In this study, we have documented the time course of changes in the retina following optic neuritis and demonstrated the rapid change from swelling to atrophy in the RNFL, which occurs in the first months after optic neuritis. From the data presented here, it appears that thinning of the affected eye RNFL relative to the fellow eye first typically appears within 1–2 months (Fig. 2) and at least half of the eventual RNFL loss that occurs is evident after 3 months (Table 1). This finding is in keeping with earlier studies serially examining optic nerve mean area following optic neuritis (Hickman et al., 2004a), and with pathological studies indicating the proportion of axonal loss is greatest in early and acutely inflammatory lesions (Ferguson et al., 1997; Kornek et al., 2000). The model predicts that there is an ongoing but very slow rate of loss at 12 months, which is concordant with radiological (Hickman et al., 2004a) and pathological data suggesting a low grade inflammation and axonal loss which persists for some time following the acute inflammatory episode (Kornek et al., 2000). This may also be due, in part, to a post-inflammatory phase in which the axon is demyelinated and lacking the trophic support of oligodendrocytes (Wilkins and Compston, 2005) and vulnerable to toxicity from compounds such as nitric oxide (Smith et al., 2001). There may also be ongoing atrophy with slow clearance of phagocytosed debris associated with Wallerian degeneration.

The speed of RNFL thinning in the first 3 months was significantly greater in those patients with an eventual poor recovery. The decrease in RNFL thickness seen in the whole period of this study, occurring from a baseline of swelling in the RNFL, is probably composed of two components: resolution of inflammation and oedema on the one hand and loss of tissue due to axonal death and Wallerian degeneration on the other. Although it is not possible to establish which component predominates in the early months (optical coherence tomography does not distinguish between these two processes), because the extent of swelling per se did not predict visual recovery, it seems that the more rapid decline in RNFL thickness in the poor recovery group reflects a greater extent of early axonal loss in this cohort (which was also confirmed to have greater axonal loss at a much later time point, when inflammation should no longer be present). By 3 months, the patients with an eventual poor visual recovery had a lower RNFL thickness than the remainder of the patients (75.5 μm for poor recovery versus 99.7 μm for good recovery, P < 0.002).

Interpretation of the model of retinal changes must be accompanied by a number of caveats. First, there are only two measures...
in the earliest phases following the onset of symptoms, which may diminish the accuracy of the model during this period. Further study with frequent imaging during the first 3 months should provide a more reliable model of early RNFL changes and their relationship to concurrent and future visual function. Secondly, newer optical coherence tomography systems that provide greater resolution of the retinal layers may also be informative (Drexler and Fujimoto, 2008), and the model may not apply to other optical coherence tomography systems that provide greater resolution of the retinal layers (analysis of covariance).

Table 4 Sample size estimates for outcome measures (retinal nerve fibre layer thickness) at 12 months (panel a), 6 months (panel b) and 3 months (panel c) for a parallel-groups, placebo-control trial

<table>
<thead>
<tr>
<th>Effect size</th>
<th>80% power Method</th>
<th>90% power Method</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>Panel a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>292</td>
<td>231</td>
</tr>
<tr>
<td>30</td>
<td>130</td>
<td>103</td>
</tr>
<tr>
<td>40</td>
<td>73</td>
<td>58</td>
</tr>
<tr>
<td>50</td>
<td>47</td>
<td>37</td>
</tr>
<tr>
<td>60</td>
<td>33</td>
<td>26</td>
</tr>
<tr>
<td>70</td>
<td>24</td>
<td>19</td>
</tr>
<tr>
<td>80</td>
<td>19</td>
<td>15</td>
</tr>
<tr>
<td>Panel b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>358</td>
<td>222</td>
</tr>
<tr>
<td>30</td>
<td>159</td>
<td>99</td>
</tr>
<tr>
<td>40</td>
<td>90</td>
<td>56</td>
</tr>
<tr>
<td>50</td>
<td>58</td>
<td>36</td>
</tr>
<tr>
<td>60</td>
<td>40</td>
<td>25</td>
</tr>
<tr>
<td>70</td>
<td>30</td>
<td>19</td>
</tr>
<tr>
<td>80</td>
<td>23</td>
<td>14</td>
</tr>
<tr>
<td>Panel c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>1024</td>
<td>608</td>
</tr>
<tr>
<td>30</td>
<td>455</td>
<td>271</td>
</tr>
<tr>
<td>40</td>
<td>256</td>
<td>152</td>
</tr>
<tr>
<td>50</td>
<td>164</td>
<td>98</td>
</tr>
<tr>
<td>60</td>
<td>114</td>
<td>68</td>
</tr>
<tr>
<td>70</td>
<td>84</td>
<td>50</td>
</tr>
<tr>
<td>80</td>
<td>64</td>
<td>38</td>
</tr>
</tbody>
</table>

Effect size: percent decrease in retinal nerve fibre layer loss comparing neuroprotective treatment versus placebo arm. Method A: Comparison of follow-up affected eye retinal nerve fibre layer, ignoring fellow eye value, as would be advisable when there is a history of prior optic neuritis in the fellow eye; this calculation requires the standard deviation of follow-up affected eye retinal nerve fibre layer. Method B: Comparison of difference between follow-up affected eye and baseline fellow eye retinal nerve fibre layer; this calculation requires the standard deviation of this difference. Method C: Comparison of follow-up affected eye adjusted for baseline fellow eye retinal nerve fibre layer; this calculation requires the follow-up affected eye retinal nerve fibre layer standard deviation and the Pearson correlation coefficient for follow-up affected versus baseline fellow eye retinal nerve fibre layer (analysis of covariance).
required in such a trial are substantially smaller if outcome measures can be adjusted for a clinically unaffected fellow eye. This outcome measure overcomes the large inter-subject variability in normal RNFL thickness that will impact sample size calculations using the absolute RNFL measure as an outcome. Overall sample sizes for detecting a moderate 50% neuroprotective effect at 6 months—inferred from a 50% reduction in the amount of RNFL loss compared to the fellow eye in a trial comparing active and placebo arms—are ~35 per arm (95% CI ~20, 70) with 80% power and ~50 per arm (CI ~30, 110) with 90% power. The equivalent sample sizes for a lesser 30% neuroprotective effect at 6 months are ~100 (CI ~55, 200) and ~130 (CI ~70, 300) per arm.

When the fellow eye has already experienced an episode of optic neuritis, the final inter-eye difference is likely to be small and the actual RNFL measure of the affected eye will likely be the more suitable outcome measure, with a consequent higher sample size for the study design. Our cohort presented with clinically isolated unilateral optic neuritis and the unaffected fellow eye did not show RNFL thinning compared with controls; however, in established relapsing remitting multiple sclerosis cohorts, where RNFL reductions have been reported in fellow eyes (Fisher et al., 2006; Pulicken et al., 2007), the inter-eye RNFL thickness difference may be a less powerful outcome measure. Our cohort did not receive intravenous glucocorticosteroid treatment for their optic neuritis, although the lack of benefit of such an intervention did not receive intravenous glucocorticosteroid treatment for their optic neuritis, although the lack of benefit of such an intervention—suggested with optical coherence tomography-measured RNFL loss would appear to be a clinically unaffected fellow eye. This outcome measure—suggested with optical coherence tomography-measured RNFL loss would appear to be a small. Overall, optical coherence tomography of the affected eye will likely be the more suitable outcome measure for evaluating putative experimental neuroprotective treatments in acute optic neuritis.

Acknowledgements
The authors thank the study participants.

Funding
The NMR Research Unit is supported by the Multiple Sclerosis Society of Great Britain and Northern Ireland and the Department of Health’s Comprehensive Biomedical Research Centre at University College Hospitals Trust. P. G. Schlottmann was supported by The Guide Dogs for the Blind Association.

Supplementary material
Supplementary material is available at Brain online.

References


